The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

In this study, participants with TRD were randomly assigned to receive intranasal Spravato monotherapy at either 56mg or 84mg, administered twice weekly, or placebo nasal spray for 4 weeks.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

doses of Spravato achieved MDD remission with an MADRS total score of less than or equal to 12, and 18.3% of those on 56 mg does achieved remission, compared to 7.6% of participants taking the ...

Opens in a new tab or window The FDA approved esketamine (Spravato) nasal spray as monotherapy ... with least-square mean differences of -5.1 with the 56-mg dose and -6.8 with the 84-mg dose.

The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the approval of Spravato for treatment-resistant depression. PE: How does ...

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the FDA has blessed the nasal spray to be used as a monotherapy for major ...

Now, the Food and Drug Administration (FDA) has expanded approval for Johnson & Johnson's nasal spray, Spravato, to be used as a standalone treatment for people with severe depression who haven't ...